Seasonal Allergic Rhinitis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Seasonal Allergic Rhinitis - Pipeline Review, H2 2016', provides an overview of the Seasonal Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seasonal Allergic Rhinitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Seasonal Allergic Rhinitis - The report reviews pipeline therapeutics for Seasonal Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Seasonal Allergic Rhinitis therapeutics and enlists all their major and minor projects - The report assesses Seasonal Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Seasonal Allergic Rhinitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Seasonal Allergic Rhinitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Seasonal Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Seasonal Allergic Rhinitis Overview 6 Therapeutics Development 7 Pipeline Products for Seasonal Allergic Rhinitis - Overview 7 Seasonal Allergic Rhinitis - Therapeutics under Development by Companies 8 Seasonal Allergic Rhinitis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Seasonal Allergic Rhinitis - Products under Development by Companies 11 Seasonal Allergic Rhinitis - Companies Involved in Therapeutics Development 12 Allergy Therapeutics Plc 12 Faes Farma, S.A. 13 Glenmark Pharmaceuticals Ltd. 14 Hisamitsu Pharmaceutical Co., Inc. 15 Merck & Co., Inc. 16 Pfizer Inc. 17 Shionogi & Co., Ltd. 18 VentiRx Pharmaceuticals, Inc. 19 Seasonal Allergic Rhinitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 asapiprant - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 bilastine - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 desloratadine - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 emedastine difumarate - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 GSP-301 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 PF-06444752 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 PF-06444753 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Pollinex Quattro Tree - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 VTX-1463 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Seasonal Allergic Rhinitis - Dormant Projects 43 Seasonal Allergic Rhinitis - Discontinued Products 45 Seasonal Allergic Rhinitis - Product Development Milestones 46 Featured News & Press Releases 46 May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis 46 Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN 46 Oct 11, 2013: FDA Approves Sanofi's Nasacort Allergy 24HR for Over-the-Counter Use 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Number of Products under Development for Seasonal Allergic Rhinitis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Seasonal Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2016 12 Seasonal Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016 13 Seasonal Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 14 Seasonal Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 15 Seasonal Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016 16 Seasonal Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016 17 Seasonal Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016 18 Seasonal Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Seasonal Allergic Rhinitis - Dormant Projects, H2 2016 43 Seasonal Allergic Rhinitis - Dormant Projects (Contd..1), H2 2016 44 Seasonal Allergic Rhinitis - Discontinued Products, H2 2016 45
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.